Phase I Study to Compare CMAB818 Injection and Lucentis® in Patients With Wet AMD
Status:
Recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, two-group parallel, positive-controlled clinical Phase I
trial comparing the safety, pharmacokinetics, pharmacodynamics and efficacy of CMAB818 and
Lucentis® in patients with wet age-related macular degeneration.